All Outputs (2)

The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity (2014)
Journal Article
Gill, J., Loadman, P., Shnyder, S., Cooper, P., Atkinson, J., Ribeiro Morais, G., …Falconer, R. (2014). The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity. Molecular Pharmaceutics, 11(4), 1294-1300. https://doi.org/10.1021/mp400760b

Development of therapeutic strategies for tumor-selective delivery of therapeutics, through exploitation of the proteolytic tumor phenotype, has significant scope for improvement of cancer treatment. ICT2588 is a peptide-conjugated prodrug of the vas... Read More about The Tumor-Targeted Prodrug ICT2588 Demonstrates Therapeutic Activity Against Solid Tumors and Reduced Potential For Cardiovascular Toxicity.

Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy (2014)
Journal Article
Ansari, C., Tikhomirov, G., Hong, S., Falconer, R., Loadman, P., Gill, J., …Daldrup-Link, H. (2014). Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy. Small, 10(3), 566-575. https://doi.org/10.1002/smll.201301456

Vascular disrupting agents (VDA) offer a strategy to starve solid tumors of nutrients and oxygen concomitant with tumor shrinkage. Several VDAs have progressed into early clinical trials, but their therapeutic value seems to be compromised by systemi... Read More about Development of Novel Tumor-Targeted Theranostic Nanoparticles Activated by Membrane-Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy.